Anti-VEGF drugs are suggested to use in the treatment of choroidal neovascularization secondary to pathological myopia to improve patients’ visual acuity and reduce central foveal thickness (CFT) (weak recommendation with moderate certainty evidence). Here, VEGFA is linked to choroidal neovascularization.